Sernivo spray is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older
Dr Reddy’s US subsidiary, Promius Pharma, has received approval for Sernivo (betamethasone dipropionate) spray, 0.05 per cent from the US Food and Drug Administration (FDA). Sernivo spray, a prescription topical steroid, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older. The commercial launch of the product is planned for the coming quarter.
Promius has conducted two successful multi-center, randomised, double-blind, vehicle-controlled clinical trials in subjects aged 18 years and older with moderate plaque psoriasis to evaluate the safety and efficacy of Sernivo spray. In both trials, randomised subjects applied Sernivo spray or vehicle spray to the affected areas twice daily for 28 days. Enrolled subjects had body surface area of involvement between 10 per cent to 20 per cent, and an Investigator Global Assessment (IGA) score of three (moderate).
Commenting on the approval, GV Prasad, Co-Chairman and Chief Executive Officer, Dr Reddy’s Laboratories said, “The FDA approval of Sernivo spray is a significant milestone for Promius, as it validates our committed efforts and resources to developing differentiated dermatology products from concept to commercial launch. We are delighted to receive a first round FDA approval of Sernivo spray as we look to expand our portfolio of medical dermatology products available in the US market.”
EP News Bureau – Mumbai